Acute Myeloid Leukemia (AML) with 11q23-abnormality is a specific cytogenetic subtype of AML characterized by rearrangements of the KMT2A gene (formerly known as the MLL gene) located on chromosome 11 at the q23 locus. This condition is often associated with a monocytic or myelomonocytic differentiation (corresponding to FAB M4 or M5 categories) and frequently presents with high white blood cell counts and extra-medullary involvement. The code C92.60 specifically identifies cases that are newly diagnosed, failing treatment, or have not yet reached a state of complete remission (defined as less than 5% blasts in the bone marrow and normalization of peripheral blood counts). This genetic subtype is generally considered to have an intermediate to poor prognosis, depending on the specific fusion partner and the patient's age and clinical response to induction chemotherapy.
Explicitly identify the molecular abnormality 11q23 (KMT2A/MLL) within the diagnosis line to justify the C92.6 series specificity.
Example: Assessment: Acute myeloid leukemia with 11q23-abnormality (KMT2A rearrangement confirmed by FISH), not having achieved remission. Patient is currently on Day 14 post-induction with persistent 25 percent blasts. Plan: Continue aggressive supportive care and monitor for cytopenias. Billing Focus: C92.60 for the specific genetic marker. Risk Adjustment: High HCC impact due to active malignancy status and chemotherapy-induced pancytopenia.
Billing Focus: Identify the genetic subtype specifically as 11q23 rather than unspecified AML (C92.00).
Clearly document the remission status using standardized terminology such as not having achieved remission, in remission, or in relapse.
Example: Status: Acute myeloid leukemia with 11q23-abnormality, not having achieved remission. Bone marrow biopsy from 10/24/2025 shows 40 percent myeloblasts despite initial 7 plus 3 induction. Comorbidities: Type 2 diabetes with hyperglycemia, which complicates steroid use in treatment. Risk Adjustment: Specificity in remission status determines the exact ICD-10 code (C92.60 vs C92.61).
Billing Focus: Remission status is required for the 5th character in the C92 series.
Incorporate flow cytometry and cytogenetic results directly into the assessment and plan to support the medical necessity of high-complexity E/M services.
Example: Clinical Note: Patient with AML and 11q23-abnormality. Flow cytometry shows CD33 positive blasts. Cytogenetics confirm t(4;11)(q21;q23). Current status is not having achieved remission. Patient is symptomatic with grade 3 fatigue and mucositis. Billing Focus: High complexity MDM for 99215 due to life-threatening condition and treatment toxicity. Risk Adjustment: Presence of specific translocations may influence prognosis and risk scores.
Billing Focus: Evidence of diagnostic complexity supports High MDM (99215).
Document all associated hematologic manifestations such as anemia, neutropenia, and thrombocytopenia as separate diagnoses when present.
Example: Impression: Acute myeloid leukemia with 11q23-abnormality, not having achieved remission. Secondary diagnoses: Acute blood loss anemia (Hgb 6.4), febrile neutropenia (ANC 100), and severe thrombocytopenia requiring daily platelet transfusions. Billing Focus: Code each cytopenia to reflect the full clinical burden. Risk Adjustment: Comorbid cytopenias increase the overall risk score and complexity.
Billing Focus: Each cytopenia should be coded to provide a complete picture of the patient's acuity.
Differentiate between de novo AML and AML following a myelodysplastic syndrome or therapy-related AML.
Example: Diagnosis: Therapy-related acute myeloid leukemia with 11q23-abnormality following previous treatment for breast cancer (C50.911), not having achieved remission. Current bone marrow shows significant dysplasia in the erythroid line. Billing Focus: Use C92.60 but ensure the history of prior malignancy (Z85.3) is noted if relevant. Risk Adjustment: Therapy-related AML often carries a poorer prognosis and higher complexity.
Billing Focus: Ensures the specific cause/type of AML is captured if it meets therapy-related criteria.
AML patients not in remission usually require High MDM due to the life-threatening nature of the disease and the toxicities of therapy.
Initial consultation for newly diagnosed AML with 11q23 abnormality involves complex diagnostic review and treatment planning.
Essential for confirming the diagnosis of AML and assessing the percentage of blasts to determine remission status.
Used for flow cytometry and cytogenetic testing to identify the 11q23-abnormality.
Necessary to distinguish AML from ALL and to identify specific phenotypic markers in 11q23 AML.
Directly identifies the 11q23-abnormality required to code C92.60 correctly.
Standard of care for inducing remission in AML patients.
Used for routine follow-up during stable phases or for minor complications during treatment.
Rarely used for C92.60 due to the inherent complexity of active AML, but may be used for very straightforward supportive care checks.
Frequent requirement for AML patients not in remission due to marrow replacement and chemo effects.